Freenome (FRNM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Aug, 2026Executive summary
An extraordinary general meeting is called to vote on extending the deadline to complete a business combination from June 13, 2026 to June 13, 2027, and to allow adjournment if necessary.
The extension is sought to provide more time to finalize a previously announced business combination with Freenome Holdings, Inc., though completion is not guaranteed.
If the extension is not approved and no business combination is completed by the original deadline, the company will liquidate and redeem public shares.
Shareholders may redeem their shares for a pro rata portion of the trust account, with the redemption price estimated at $10.78 per share as of May 1, 2026.
The board unanimously recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Amend the Memorandum and Articles of Association to extend the business combination deadline by one year.
Proposal 2: Adjourn the meeting if there are insufficient votes or excessive redemptions threaten Nasdaq listing requirements.
Approval of Proposal 1 requires a two-thirds majority; Proposal 2 requires a simple majority.
Only these two proposals will be considered at the meeting; no director elections or other matters are on the agenda.
Board of directors and corporate governance
The board, including initial shareholders holding 22.1% of voting power, intends to vote all their shares in favor of both proposals.
The sponsor and directors have waived redemption rights for their shares and will not participate in liquidation distributions.
The sponsor is affiliated with Perceptive Advisors, a major life sciences investment firm.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024 - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024